PRIMARY STUDY
Cannabidiol Counteracts Amphetamine-Induced Neuronal And Behavioral Sensitization Of The Mesolimbic Dopamine Pathway Through A Novel MTOR/p70S6 Kinase Signaling Pathway
Key Findings: The cannabis-derived phytochemical, cannabidiol (CBD), has been shown to have pharmacotherapeutic efficacy for the treatment of schizophrenia. The findings demonstrate a novel mechanism for the putative antipsychotic-like properties of CBD in the mesolimbic circuitry
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Canada
Year of Pub: 2016
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
Citation: Renard J, et al. Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway. J Neurosci. 2016; 36:5160-9. doi: 10.1523/JNEUROSCI.3387-15.2016
Authors: Renard J, Loureiro M, Rosen LG, Zunder J, de Oliveira C, Schmid S, Rushlow WJ, Laviolette SR
